Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$6.84
+0.01 (+0.15%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-39.2M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.0B
P/E
52.6x
↑EV/EBITDA
10.4x
↓ROE
3.0%
↑Gross Margin
17.5%
↓Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.7%
FCF CAGR
—
FCF margin
14.8%
FCF / Net income
5.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.20B · net income $171.3M · FCF $916.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.20B | $6.20B | $6.02B | $5.41B | $5.89B |
| Net Income | $171.3M | $171.3M | $70.9M | $403.1M | $550.1M |
| EBITDA | $593.3M | $593.3M | $458.3M | $728.2M | $904.6M |
| EPS | 0.17 | 0.17 | 0.07 | 0.39 | 0.54 |
| Gross Margin | 17.5% | 17.5% | 16.4% | 19.8% | 21.6% |
| Operating Margin | 1.1% | 1.1% | 0.9% | 4.4% | 6.8% |
| Net Margin | 2.8% | 2.8% | 1.2% | 7.5% | 9.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.18 | 0.25 | 0.06 |
| Current Ratio | 1.73 | 1.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $916.3M | $916.3M | $-39.2M | $-270.2M | $-686.2M |
| Returns | |||||
| ROE | 3.0% | 3.0% | 1.3% | 7.3% | 10.4% |
| Valuation | |||||
| P/E | 52.62 | 52.62 | 88.47 | 30.35 | 22.35 |
| EV/EBITDA | 10.38 | 10.38 | 15.91 | 18.67 | 13.95 |
| P/B | 1.23 | 1.23 | 1.14 | 2.22 | 2.32 |
| Growth & Yield | |||||
| Revenue Growth | 3.1% | 3.1% | 11.3% | -8.2% | — |
| EPS Growth | 141.8% | 141.8% | -82.4% | -26.9% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
53.5%
EPS terminal req.
$0.61
Spread vs growth
88.3%
5Y implied EPS CAGR
34.3%
EPS terminal req.
$0.73
Spread vs growth
107.4%
10Y implied EPS CAGR
21.6%
EPS terminal req.
$1.18
Spread vs growth
120.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.8%
Start / end P/E
103.9x → 40.8x
EPS bridge
0.07 → 0.17
Residual
-86.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.